Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura C Coates

Showing results (81-90 of 342) with videos related to

Pageof 35
Sort By:
Rheumatology (Oxford, England)|September 19, 2025
Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two yearsPhilip J Mease, Laura C Coates, Corine Gaillez, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
GRAPPA Treatment Recommendations: Updates and MethodsArthur Kavanaugh, Laura C Coates, Danielle A van der Windt, et al.
The Journal of Rheumatology|February 16, 2021
GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual MeetingLaura C Coates, Nadia Corp, Danielle A van der Windt, et al.
Rheumatology (Oxford, England)|September 11, 2019
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trialLaura C Coates, Farrouq Mahmood, Jane Freeston, et al.
The Lancet. Rheumatology|January 31, 2024
Treat-to-target in psoriatic arthritis-cost-effective in the biosimilar eraLaura C Coates, John O'Dwyer, David Meads, et al.
Advances in Therapy|May 5, 2026
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic ArthritisChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
The Journal of Rheumatology|August 1, 2023
Diversity, Equity, and Inclusion: Sex and Gender and Intersectionality With Race and Ethnicity in Psoriatic DiseaseLihi Eder, Alaina J James, Irene van der Horst-Bruinsma, et al.
RMD Open|February 20, 2020
Treat-to-target in PsA: methods and necessityEmma Dures, Sasha Shepperd, Sandeep Mukherjee, et al.
RMD Open|April 24, 2023
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 studyLaura C Coates, Philip J Mease, Dafna D Gladman, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual MeetingLaura C Coates, Nadia Corp, Danielle A van der Windt, et al.
Pageof 35

Showing results (81-90 of 342) with videos related to

Sort By:
Pageof 35
Rheumatology (Oxford, England)|September 19, 2025
Relationship of radiographic progression status to low disease activity in patients with psoriatic arthritis receiving secukinumab treatment for two yearsPhilip J Mease, Laura C Coates, Corine Gaillez, et al.
The Journal of Rheumatology. Supplement|June 3, 2020
GRAPPA Treatment Recommendations: Updates and MethodsArthur Kavanaugh, Laura C Coates, Danielle A van der Windt, et al.
The Journal of Rheumatology|February 16, 2021
GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual MeetingLaura C Coates, Nadia Corp, Danielle A van der Windt, et al.
Rheumatology (Oxford, England)|September 11, 2019
Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trialLaura C Coates, Farrouq Mahmood, Jane Freeston, et al.
The Lancet. Rheumatology|January 31, 2024
Treat-to-target in psoriatic arthritis-cost-effective in the biosimilar eraLaura C Coates, John O'Dwyer, David Meads, et al.
Advances in Therapy|May 5, 2026
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic ArthritisChristopher T Ritchlin, Laura C Coates, Philip J Mease, et al.
The Journal of Rheumatology|August 1, 2023
Diversity, Equity, and Inclusion: Sex and Gender and Intersectionality With Race and Ethnicity in Psoriatic DiseaseLihi Eder, Alaina J James, Irene van der Horst-Bruinsma, et al.
RMD Open|February 20, 2020
Treat-to-target in PsA: methods and necessityEmma Dures, Sasha Shepperd, Sandeep Mukherjee, et al.
RMD Open|April 24, 2023
Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 studyLaura C Coates, Philip J Mease, Dafna D Gladman, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual MeetingLaura C Coates, Nadia Corp, Danielle A van der Windt, et al.
Pageof 35